BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...using engineered and wild-type bacteria for biotherapeutic, OTC...
BioCentury | Sep 11, 2020
Product Development

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

...to energize the development of app-enabled over-the-counter (OTC...
BioCentury | Jun 1, 2020
Deals

Intellia deal expands Regeneron’s reach into CRISPR therapies

Fresh off Sanofi’s sell-off, Regeneron announced an expanded collaboration with gene editing company Intellia that gives the big biotech access to the coveted CRISPR gene editing technology for additional targets and indications, including hemophilia. The...
BioCentury | Jan 10, 2020
Clinical News

Gene therapy readout helps Ultragenyx rebound

...cohort of three patients in a Phase I/II trial of DTX301 to treat ornithine transcarbamylase (OTC...
...an adeno-associated virus serotype 8 (AAV8) vector designed to deliver stable expression and activity of OTC...
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...were not disclosed. Separately, Takeda gained $660 million by divesting a portfolio of about 20 OTC...
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...liquidity and could obtain a higher valuation compared with its National Equities Exchange and Quotations OTC...
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

...device risk regulation, Class II, meaning FDA can designate them for either prescription or over-the-counter (OTC...
...website but launched KinesiaU in 2019; (C) Some models of the Propeller System are available OTC...
BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...the application.” Lumateperone is a 5-HT2A antagonist and dopamine receptor phosphoprotein modulator. Sanofi takes U.S. OTC...
...in the U.S. to prevent and treat influenza, and gains rights for first negotiations for OTC...
BioCentury | Jul 19, 2019
Financial News

Genmab’s plans after $500M NASDAQ debut

...The offering price valued Genmab at $11.4 billion and provides the company, which was traded OTC...
BioCentury | May 18, 2019
Product Development

AAVs on the brink: Charting the clinical landscape of in vivo gene therapies

...trial are not shown. Neurocrine Biosciences Inc. (NASDAQ:NBIX) and Voyager Therapeutics Inc. (NASDAQ:VYGR) are partnered. OTC...
Items per page:
1 - 10 of 815